araag2/HINT huggingface dataset:
Clinical trial NCT02271503 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: cd-ld ir, ipx203 180 mg, ipx203 270 mg, rytary 195 mg, rytary 145 mg
SMILES: C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

        Male or female subjects diagnosed with idiopathic PD with motor complications, who are
        currently being treated chronically with stable regimens of CD-LD.

        Requiring at least 400 mg but not more than 1600 mg LD per day during the waking hours; and
        at least 100 mg but not more than 250 mg LD from IR CD-LD for the first morning dose.

        Dosing frequency of IR CD-LD of at least 4 times daily excluding nighttime dosing.

        Have an average of at least 2 hours per day "off" time during the waking hours and at least
        1 hour "off" time per day, based on the PD diary collected for 3 consecutive days prior to
        Visit 1.

        Exclusion criteria:

        Have used first morning dose of controlled-release (CR) CD-LD or Rytary for at least 4
        weeks prior to Visit 1.

        Female subjects who are currently breastfeeding or lactating.

        Had prior functional neurosurgical treatment for PD (ablation or deep brain stimulation) or
        if such procedure(s) are planned or anticipated during the study period.

        Allergic to study drugs

        History of medical conditions or of a prior surgical procedure that would interfere with LD
        absorption, such as gastrectomy or small-bowel resection.

        History of peptic ulcer disease or upper gastrointestinal hemorrhage.

        History of narrow angle glaucoma.

        History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias;
        neuroleptic malignant syndrome; or nontraumatic rhabdomyolysis.

        History of psychosis.

        Employees or family members of the Investigator, study site, or Sponsor.

        Subjects who, in the opinion of the clinical investigator, should not participate in the
        study.

        Based on clinical assessment, subject does not adequately comprehend the terminology needed
        to complete the PD diary.
Clinical trial NCT02272634 (phase 2, status: unknown status)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: ypl-001 low dose, ypl-001 high dose, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult males and/or females, 40 to 80 years of age (inclusive).

          -  History of COPD for at least 12 months prior to screening.

          -  Diagnosed with COPD as defined by the American Thoracic Society (ATS)/European
             Respiratory Society (ERS) guidelines with symptoms compatible with COPD for at least
             12 months prior to screening.

          -  Classified as moderate to severe COPD based on the current severity classification
             GOLD Stage 2-3 disease in terms of post-bronchodilator spirometry at screening

          -  etc.

        Exclusion Criteria:

          -  History of life-threatening COPD including respiratory arrest, intensive care unit
             admission and/or requiring intubation.

          -  History of more than 2 hospitalizations for COPD within 12 months prior to screening.

          -  Presentation of an acute exacerbation of COPD that will be associated with increase
             sputum volume or change in sputum color within 4 weeks before Day 1 of the Run-in
             Period.

          -  Evidence of pulmonary heart disease, or clinically significant pulmonary hypertension.

          -  etc.
Clinical trial NCT02272803 (phase 2, status: active, not recruiting)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: lenalidomide, dexamethasone
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Newly diagnosed with symptomatic Multiple Myeloma (MM)

          -  Have not received any prior systemic anti-myeloma therapy

          -  Have measurable disease

          -  Are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because
             of age (≥ 65 years) or coexisting conditions. Refusal to undergo high dose therapy
             with SCT is NOT sufficient for entry onto CA204-116 for a subject < 65 years old.
             There must be a comorbidity that prevents SCT for a subject < 65 years old

        Exclusion Criteria:

          -  Non-secretory myeloma

          -  Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions

          -  Monoclonal Gammopathy of Undetermined Significance (MGUS)

          -  Active plasma cell leukemia

          -  Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
Clinical trial NCT02276989 (phase 2, status: withdrawn)
Conditions: compliance, chronic pain
ICD codes: G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3
Drugs: acetazolamide, quinine, riboflavin
SMILES: COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O, [H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12, CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1
Reason stopped: 
    poor recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          1. male and female English-speaking literate adults age 18- 50 years old,

          2. have medically diagnosed chronic pain condition,

          3. be on a stable dose of buprenorphine (clinic modal dose),

          4. history of prescription opioid abuse,

          5. adequate venous access,

          6. if female, a negative pregnancy test. Individuals will not be accepted who are
             unstable in buprenorphine treatment as evidence by continued illicit drug use and
             irregular clinic attendance in the previous trial,

          7. be otherwise in good physical health or in care of a physician who is wiling to take
             responsibility for such treatment. The same conditions apply in cases of patients with
             a psychiatric disorder needing ongoing treatment.

        Exclusion Criteria:

          1. physiologic drug dependence on benzodiazepines, barbiturates, and/or alcohol that
             would require medical management,

          2. significant ongoing medical problems (e.g., diabetes),

          3. history of head injury or seizure,

          4. serious psychiatric illness outside of drug use (e.g., schizophrenia),

          5. recent use of any agent that inhibits or induces cytochrome P450 3A4 or 2D6,

          6. nursing or pregnant female, or a female or male who does not agree to not become
             pregnant or father a child during the course of, and three months following completion
             of the study,

          7. have a cardiac conduction or blood clotting disorder,

          8. blood donation within the past 30 days prior to screening,

          9. clinically significant laboratory results (as judged by the
             investigator/sub-investigator)

         10. moderate to severe COPD,

         11. renal impairment, and

         12. severe renal hepatic impairment.
Clinical trial NCT02277106 (phase 2, status: completed)
Conditions: essential tremor
ICD codes: G25.0
Drugs: sage-547, placebo
SMILES: [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, 35-75 years old with a diagnosis of essential tremor with symptoms
             clearly present in at least 1 upper limb; patient has had tremor present for at least
             2 years prior to Screening

          -  Off medication, or on a stable dose of medication for their tremor for at least 28
             days prior to Screening

        Exclusion Criteria:

          -  Recent history or active clinically significant manifestations of metabolic, hepatic,
             renal, hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal,
             dermatological, urogenital, eyes, ears, nose, or throat, psychiatric, or neurological
             (other than essential tremor) disorders

          -  Medical history of seizures
Clinical trial NCT02278471 (phase 2, status: completed)
Conditions: hypertension, hyperlipidemia
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10, E78.2, E78.49, E78.5
Drugs: polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)
SMILES: CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Enrolled at the SCCS site in Mobile, Alabama, obtain care at Franklin Primary Health
             Center, or live in the surrounding area.

          -  Aged 45-75 years

          -  Baseline systolic blood pressure ≥120 mm Hg. In this open-label trial, the study
             physicians are permitted to prescribe any additional medication deemed appropriate to
             achieve blood pressure control.

        Exclusion Criteria:

          -  History of coronary heart disease or stroke

          -  History of cancer, except for basal cell skin cancer

          -  History of liver disease, not including chronic, clinically-stable hepatitis

          -  Laboratory evidence of hepatic dysfunction (an alanine aminotransferase level more
             than two times the upper limit of the normal range)

          -  Known renal disease, estimated creatinine clearance < 60

          -  Current use of more than 2 anti-hypertensive medications

          -  LDL cholesterol ≥190 mg/dl

          -  Insulin-dependent diabetes

          -  Known intolerance to any of the components of the polypill

          -  Potassium <3.4 or >5.5 mEq/L

          -  Use of medications that interact with statins, including those affecting the
             cytochrome P450 system

          -  Current use of diuretics for indications other than hypertension

          -  Comorbidities that might be expected to limit lifespan during the 12-month follow-up
             period

          -  Inability to provide consent.
Clinical trial NCT02279407 (phase 2, status: completed)
Conditions: t2 diabetes and fatty liver disease (non-alcoholic origin)
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: placebo, omega-3 carboxylic acids, dapagliflozin, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria: Provision of informed consent prior to any study specific procedures;
        Men or women ≥40 years and ≤75 years with suitable veins for cannulation or repeated
        venepuncture; Have liver fat content as assessed by MRI >5.5%; Diagnosis of Type 2 diabetes
        since at least 6 months in accordance with WHO criteria.

        Exclusion Criteria: Any condition when MRI is contraindicated such as, but not limited to,
        having a pacemaker or claustrophobia; Diagnosis or signs of Type 1 diabetes (e.g. history
        of positive islet antibodies); Creatinine clearance <60 mL/min at screening
        (Cockcroft-Gault formula).
Clinical trial NCT02281006 (phase 2, status: terminated)
Conditions: ddp, head and neck cancer, adverse effect
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, T36.0X5S, T36.3X5S, T36.4X5S, T36.5X5S, T36.6X5S, T37.0X5S, T37.4X5S
Drugs: trans-tympanic injection of a sodium thiosulfate gel
SMILES: OS(O)(=O)=S
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with newly diagnosed locally advanced (stage III or IV) squamous cell
             carcinoma of the mouth, oropharynx, hypopharynx, or larynx scheduled to be treated
             with concomitant chemoradiation including Cisplatin100 mg/m2 3 times

          -  Normal otoscopic findings and symmetrical hearing

        Exclusion Criteria:

          -  Karnofsky below 70
Clinical trial NCT02281955 (phase 2, status: active, not recruiting)
Conditions: carcinoma, squamous cell, head and neck neoplasms, oropharyngeal neoplasms
ICD codes: C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42, C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, R13.12
Drugs: cisplatin (or alternative)
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          1. ≥ 18 years of age (no upper age limit)

          2. T0-3, N0 to N2c, M0 squamous cell carcinoma of the oropharynx

          3. Biopsy proven squamous cell carcinoma that is HPV and/or p16 positive

          4. ≤ 10 pack-years smoking history or ≤ 30 pack-years smoking history WITH ≥ 5 years
             abstinence from smoking

          5. Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks
             prior to treatment

          6. ECOG Performance Status 0-1

          7. CBC/differential obtained within 8 weeks prior to treatment, with adequate bone marrow
             function defined as follows: Platelets ≥ 100,000 cells/mm3; Hemoglobin ≥ 8.0 g/dl.

          8. Adequate renal and hepatic function within 4 weeks prior to registration, defined as
             follows: Serum creatinine < 2.0 mg/dl; Total bilirubin < 2 x the institutional ULN;
             AST or ALT < 3 x the institutional ULN.

          9. Negative serum pregnancy test within 2 weeks prior to registration for women of
             childbearing potential

         10. Women of childbearing potential and male participants who are sexually active must
             practice adequate contraception during treatment and for 6 weeks following treatment.

         11. Patients must be deemed able to comply with the treatment plan and follow-up schedule.

         12. Patients must provide study specific informed consent prior to study entry

        Exclusion Criteria:

          1. Prior history of radiation therapy to the head and neck

          2. Prior history of head and neck cancer.

          3. Unresectable disease (e.g. immobile node on physical exam, nodal disease that
             radiographically involves the carotid arteries, nerves)

          4. Currently taking Disease Modifying Rheumatoid Drugs (DMRDs)

          5. Severe, active co-morbidity, defined as follows: Unstable angina and/or congestive
             heart failure requiring hospitalization within the last 6 months; Transmural
             myocardial infarction within the last 6 months; Acute bacterial or fungal infection
             requiring intravenous antibiotics at the time of registration; Chronic Obstructive
             Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization
             or precluding study therapy at the time of registration; Hepatic insufficiency
             resulting in clinical jaundice and/or coagulation defects (Note, however, coagulation
             parameters are not required for entry into this protocol); Pre-existing ≥ grade 2
             neuropathy; Prior organ transplant; Systemic lupus; Psoriatic arthritis.

          6. Known HIV positive.
Clinical trial NCT02285504 (phase 2, status: completed)
Conditions: postpartum depression
ICD codes: F53.0
Drugs: sage-547
SMILES: [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult females, 18-45 years old who experienced a Major Depressive Episode in the
             postpartum period beginning within the first 4 weeks following delivery

          -  Patient has ceased lactating, or if still lactating has already fully and permanently
             weaned their infant; if still actively breastfeeding, patient must agree to cease
             giving breast milk to their infant prior to study entry

        Exclusion Criteria:

          -  Recent history or active clinically significant manifestations of metabolic, hepatic,
             renal, hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal,
             dermatological, urogenital, or eyes, ears, or nose and throat (EENT) disorders

          -  Active psychosis

          -  Medical history of seizures
Clinical trial NCT02285855 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: metformin
SMILES: CSCC[C@H](N)C(O)=O
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with pathologic diagnosis of lung NSCLC or squamous cell carcinoma.

          2. Patients are to be treated with hypofractionated RT.

          3. Patient is not a surgical candidate due to medical comorbidities determined by a
             thoracic surgeon or patient refusal

          4. Patient plans to receive treatment at MD Anderson

          5. Patients must sign informed consent

          6. Patient must have adequate renal function within 30 days prior to registration,
             defined as serum creatinine within normal institutional limits or creatinine clearance
             at least 60 ml/min

        Exclusion Criteria:

          1. Patient has: random glucose >200 mg/dl or is taking an oral hypoglycemic agent or
             insulin at the time of study entry

          2. Patient has a history of lactic acidosis, chronic kidney disease or a creatinine >/=
             1.2 mg/dl

          3. Women who are pregnant or breast feeding, as treatment involves unforeseeable risks to
             the participant, embryo, fetus, or nursing infant

          4. Patients with history of allergic reaction to metformin
Clinical trial NCT02287818 (phase 2, status: completed)
Conditions: gout
ICD codes: M10.9, M10.08, M10.00, M10.011, M10.012, M10.019, M10.021
Drugs: placebo, ac-201, febuxostat
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O, CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female age 20 to 65 years, inclusive.

          2. Meets ≥6 of the 12 American College of Rheumatology preliminary criteria (1977) for
             the classification of acute arthritis of primary gout (Appendix 2), OR have proven
             tophus or documented monosodium urate (MSU) crystals in the joint fluid.

          3. Serum uric acid ≥7.5 mg/dL and ≤10 mg/dL at screening with ≥1 gouty arthritis flare
             within one year prior to screening, OR serum uric acid ≥9 mg/dL and ≤10 mg/dL at
             screening with or without prior gout flares.

        Exclusion Criteria:

          1. Use of allopurinol, febuxostat, benzbromarone, probenecid, or sulfinpyrazone within 2
             weeks prior to screening.

          2. Occurrence of a gouty arthritis flare within 1 week prior to screening or during the
             screening period through baseline.

          3. Use of colchicine within 1 week prior to screening.

          4. Use of Glucocorticoids, NSAIDs or COX-2 inhibitors within 1 week prior to screening.

          5. Allergy, contraindication, or intolerance to febuxostat.

          6. Severe renal impairment.

          7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentration >2
             times the upper limit of laboratory normal range (>2x ULN) at screening.
Clinical trial NCT02288845 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: iti-007
SMILES: [H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with schizophrenia who are drug-free with regard to their antipsychotic
             medication

          -  In clinical remission and free from acute exacerbation of their psychosis

          -  In good health

        Exclusion Criteria:

          -  Clinically significant medical conditions considered inappropriate for trial
             participation
Clinical trial NCT02289417 (phase 2, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: apremilast, placebo
SMILES: [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Subjects must satisfy the following criteria to be enrolled in the study:

          -  Male or female aged 18 and over at the time of signing the informed consent.

          -  Must understand and voluntarily sign an informed consent form prior to any study
             related assessments/procedures being conducted.

          -  Diagnosis of ulcerative colitis (UC) with a duration of at least 3 months prior to the
             Screening Visit..

          -  Total Mayo Score (TMS) ≥ 6 to ≤ 11 (range: 0-12) at baseline, prior to randomization
             in the study.

          -  Endoscopic subscore ≥ 2 (range: 0-3) on the Mayo score prior to randomization in the
             study.

          -  Subjects must have had a therapeutic failure, been intolerant to, or have a
             contraindication to, at least one of the following: oral aminosalicylates (ie,
             5-aminosalicylic acid [5-ASA] compounds or sulfasalazine [SSZ]), budesonide, systemic
             corticosteroids, or immunosuppressants (eg, 6-mercaptopurine [6-MP], azathioprine
             [AZA], or methotrexate [MTX]).

        Exclusion Criteria:

        The presence of any of the following will exclude a subject from enrollment:

          -  Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic
             colitis, radiation colitis or diverticular disease-associated colitis.

          -  Ulcerative colitis restricted to the distal 15 cm or less (eg, ulcerative proctitis).

          -  Subjects who have had surgery as a treatment for UC or who, in the opinion of the
             Investigator, are likely to require surgery for UC during the study.

          -  Clinical signs suggestive of fulminant colitis or toxic megacolon.

          -  Prior use of any tumor necrosing factor (TNF) inhibitor (or any biologic agent).

          -  Prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine or thalidomide.

          -  Use of intravenous (IV) corticosteroids within 2 weeks of the Screening Visit.

          -  Use of immunosuppressants (AZA, 6-MP or MTX) within 8 weeks of the Screening Visit.

          -  Use of topical treatment with 5-ASA or corticosteroid enemas or suppositories within 2
             weeks of the Screening Visit.

          -  History of any clinically significant neurological, renal, hepatic, gastrointestinal,
             pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder
             or disease, or any other medical condition that, in the investigator's opinion, would
             preclude participation in the study.